Drugs / Lunresertib

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT06107868 Mar 2024 → Oct 2025 overdue metastatic malignant neoplasm, ovarian cancer, uterine cancer University Health Network, Toronto Active not recruiting No outcome recorded
Phase 1 NCT05147350 Aug 2022 → Feb 2025 neoplasm Debiopharm International SA Terminated No outcome recorded
Phase 1 NCT05147272 Dec 2021 → Aug 2024 Debiopharm International SA Terminated No outcome recorded
Phase 1 NCT04855656 Apr 2021 → Dec 2027 expected neoplasm Debiopharm International SA Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT05601440 Jun 2023 → Dec 2027 expected female breast carcinoma Canadian Cancer Trials Group Recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05605509 Comparator May 2023 → Nov 2025 cancer of unknown primary site Canadian Cancer Trials Group Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Lunresertib ClinicalTrials.gov intervention name — accepted as the source's own label NCT04855656
Known as (R)-LUNRESERTIB ChEMBL registry synonym — accepted as the source's own label CHEMBL5199076
Known as (R)-RP 6306 ChEMBL registry synonym — accepted as the source's own label CHEMBL5199076
Known as (RAC)-LUNRESERTIB ChEMBL registry synonym — accepted as the source's own label CHEMBL5199076
Known as (RAC)-RP-6306 ChEMBL registry synonym — accepted as the source's own label CHEMBL5199076
Known as RP-6306 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05147272
4

NCT05147350

NCT05605509

NCT05601440

NCT06107868

Action Inhibit “Oral PKMYT1 Inhibitor” NCT04855656
Modality Small molecule CHEMBL5199076
Route Oral “administered orally” NCT04855656
Target PKMYT1 “Oral PKMYT1 Inhibitor” NCT04855656